Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide Titration in Chinese T2D Patients
NCT04235959Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tirzepatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) at 43 weeks. Started Oct 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04235959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04235959.